Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Oncology Nursing News

Pediatric Oncology

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

Sarcomas/TGCT

Supportive Care

Jonathan W. Riess, MD, MS, and James Chih-Hsin Yang MD, PhD, debate the benefits of upfront osimertinib with/without chemotherapy in EGFR-mutant NSCLC.

Experts Weigh in on Topic of Frontline Osimertinib Alone or With Chemo in EGFR-Mutant NSCLC 

Jacob Sands, MD, discusses updates to the role of antibody-drug conjugates in the treatment of patients with small cell lung cancer.

Dr Sands on the Evolving Role of ADCs in SCLC Management

Fred R. Hirsch, MD, PhD, discusses the activity of HER3-directed agents in patients with non–small cell lung cancer harboring NRG1 mutations.

Dr Hirsch on the Treatment of NRG1 Fusion+ NSCLC

Lajos Pusztai, MD, DPhil, discusses molecular residual disease monitoring in early-stage breast cancer.

MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

Articles

Michelle Mendoza, PhD, and Jeffrey Weiss, PhD, received a $2.6 million grant from the NIH to research how tension in lung tissue affects the growth and distribution of tumors. 

Mendoza, Weiss Receive $2.6 Million Grant to Study Biomechanics of Lung Tumors

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

The EMA's CHMP has recommended zolbetuximab plus chemotherapy in select locally advanced unresectable or metastatic HER2-negative gastric or GEJ cancer.

Zolbetuximab Plus Chemo Approaches EU Approval for Advanced Gastric/GEJ Cancer

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

The EMA’s CHMP has recommended the approval of amivantamab plus chemotherapy for pretreated, EGFR-mutated advanced non–small cell lung cancer.

CHMP Recommends Amivantamab Plus Chemo for Pretreated EGFR+ Advanced NSCLC

First-line sugemalimab plus chemotherapy has been approved in Europe for metastatic non–small cell lung cancer.

First-Line Sugemalimab Plus Chemo Wins European Approval for Metastatic NSCLC

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

OncLive Magazine Subscription